Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.44 |
| ▸ | ACHE | P22303 | 7/20 | 0.44 |
| ▸ | BCHE | P06276 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | UNG | P13051 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13527943 | 0.85 | ALDH1A1 (0.39) | ALDH1A1MAOAMAOBNPC1RAB9A | |
| SCHEMBL3536989 | 0.80 | ALDH1A1 (0.44) | ALDH1A1MAOAMAOBNPC1RAB9A | |
| SCHEMBL895976 | 0.78 | PTGS2 (0.62) | PTGS2ACHEBCHEALDH1A1NPC1 | |
| SCHEMBL27830252 | 0.76 | PTGS2 (0.40) | PTGS2ACHEBCHEALDH1A1NPC1 | |
| SCHEMBL4099672 | 0.75 | HDAC4 (0.53) | ALDH1A1MAOAMAOBNPC1RAB9A | |
| SCHEMBL663468 | 0.75 | MAOA (0.41) | ALDH1A1MAOAMAOBNPC1RAB9A | |
| SCHEMBL7926083 | 0.74 | AOC3 (0.44) | PTGS2ACHEBCHEALDH1A1 | |
| SCHEMBL10490641 | 0.74 | ALDH1A1 (0.41) | ALDH1A1MAOAMAOBNPC1RAB9A | |
| SCHEMBL14231960 | 0.74 | ALDH1A1 (0.41) | ALDH1A1MAOAMAOBNPC1RAB9A | |
| SCHEMBL27796753 | 0.74 | ALDH1A1 (0.41) | ALDH1A1MAOAMAOBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4570313-A2 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2025-06-18 | — | — | EP | disclosed |
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-11364241-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | MEDIVATION TECHNOLOGIES LLC (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210069191-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | MEDIVATION TECHNOLOGIES LLC | 2021-03-11 | — | — | US | disclosed |
| US-10780088-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | MEDIVATION TECHNOLOGIES LLC (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200261454-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | MEDIVATION TECHNOLOGIES LLC | 2020-08-20 | — | — | US | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-10543209-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | MEDIVATION TECHNOLOGIES LLC (US) | 2020-01-28 | — | — | US | disclosed |
| CN-105408325-B | cyanotriazole compounds | 大塚制药株式会社 | 2019-10-22 | — | — | CN | disclosed |
| US-20180117045-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | MEDIVATION TECHNOLOGIES LLC | 2018-05-03 | — | — | US | disclosed |
| US-20100022769-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | INSTITUT QUIMIC DE SARRIA CETS (ES) | 2010-01-28 | — | — | US | disclosed |
| EP-2120579-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-2100890-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | Institut Quimic De Sarria Cets (ES) | 2009-09-16 | — | — | EP | disclosed |
| EP-2100890-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | Institut Quimic De Sarria Cets (ES) | 2009-09-16 | — | — | EP | disclosed |
| US-20080269234-A1 | Such as 7-((cyclohexyl)methyl) pyrido(2,3-d )pyridazine-4(5H)-one; anticancer agents; antiinflammatory agents;antiischemic agents; antidiabetic agents | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2008083027-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080161280-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008049950-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | INSTITUT QUIMIC DE SARRIA CETS (ES) | 2008-05-02 | — | — | WO | disclosed |
| EP-0563715-B1 | Oxyalkynes, pharmaceutical compositions containing same as well as a process for the preparation of these compounds and pharmaceutical compositions | GRUENENTHAL GMBH (DE) | 1996-08-14 | — | — | EP | disclosed |
| EP-0563715-A2 | Oxyalkynes, pharmaceutical compositions containing same as well as a process for the preparation of these compounds and pharmaceutical compositions | Grünenthal GmbH (DE) | 1993-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117045-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | PTGS2 1567/4885ACHE 3312/4885BCHE 3957/4885 |
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | PTGS2 2928/4885ACHE 2953/4885BCHE 1482/4885 |
| US-20080269234-A1 | Such as 7-((cyclohexyl)methyl) pyrido(2,3-d )pyridazine-4(5H)-one; anticancer agents; antiinflammatory agents;antiischemic agents; antidiabetic agents | PARP1, DPYD, PARP2 | PTGS2 77/4885ACHE 2750/4885BCHE 3705/4885 |
| US-10780088-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | PARP1, PARP2, PARP11 | PTGS2 1567/4885ACHE 3312/4885BCHE 3957/4885 |
| US-11364241-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | PARP1, PARP2, PARP11 | PTGS2 1567/4885ACHE 3312/4885BCHE 3957/4885 |
| US-20100022769-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | MSR1, CCR5, CD4 | PTGS2 1051/4885ACHE 3563/4885BCHE 1130/4885 |
| US-10543209-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | PARP1, PARP2, PARP11 | PTGS2 1567/4885ACHE 3312/4885BCHE 3957/4885 |
| US-20200261454-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | PTGS2 1567/4885ACHE 3312/4885BCHE 3957/4885 |
| US-20080161280-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP3 | PTGS2 1959/4885ACHE 3380/4885BCHE 2912/4885 |
| US-20210069191-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | PTGS2 1567/4885ACHE 3312/4885BCHE 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.